Document and Entity Information Document Type Document Type Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Securities Act File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Condensed Consolidated Balance Sheets Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Marketable Securities, Current Investments in marketable securities Receivables, Net, Current Trade receivables, net Amount of transition services agreement receivable current. Transition Services Agreement Receivable Current TSA receivables, net Inventory, Net Inventory Prepaid Manufacturing current. Prepaid Manufacturing Expense Current Prepaid manufacturing Prepayment made for manufacturing services Prepaid Expense and Other Assets, Current Other prepaids and current assets Assets, Current Total current assets Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Property and equipment, net Inventory, Noncurrent Inventory, non-current Non-current inventory within continuing operations Intangible Assets, Net (Including Goodwill) Intangible assets, net Total Intangible assets, net Other Assets, Noncurrent Other assets, non-current Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued rebates, fees and reserve. Accrued Rebates Fees And Reserve Current Accrued rebates, fees and reserves Amount of transition services agreement payables and accrued liabilities classified as current. Transition Services Agreement Payables And Accrued Liabilities, Current TSA payables and accrued liabilities Employee-related Liabilities, Current Accrued compensation Accrued Liabilities, Current Accrued and other current liabilities Total Accrued and other current liabilities Liabilities, Current Total current liabilities Carrying value as of the balance sheet date of term loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Term Loans Payable, Noncurrent Term loan, non-current Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent. Operating and Finance Lease, Liability, Noncurrent Lease liabilities, non-current Other Liabilities, Noncurrent Other liabilities, non-current Total Other liabilities, non-current Liabilities Total liabilities Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders' equity: Common Stock, Value, Issued Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 154,217,609 and 121,154,925 at March 31, 2026 and December 31, 2025, respectively) Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Equity, Attributable to Parent Ending Balances Beginning Balances Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Ending Balances (in shares) Beginning Balances (in shares) Common stock, shares outstanding Condensed Consolidated Statements of Operations and Comprehensive Loss Revenues [Abstract] Revenue: Revenue from Contract with Customer, Including Assessed Tax Net revenue Operating Expenses [Abstract] Costs and expenses: Cost of Goods and Services Sold Cost of goods sold Research and Development Expense Research and development Selling, General and Administrative Expense Selling, general and administrative Costs and Expenses Total costs and expenses Operating Income (Loss) Loss from operations Interest Expense, Operating and Nonoperating Interest expense Other Nonoperating Income (Expense) Other income (expense), net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss from continuing operations before income taxes Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net loss from continuing operations Net loss from continuing operations Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net loss from discontinued operations, net of tax (Note 6) Net income from discontinued operations, net of tax Net loss from discontinued operations, net of tax Net loss Net loss Net Loss Per Share Net loss per share Income (Loss) from Continuing Operations, Per Basic Share Net loss per share from continuing operations - basic Income (Loss) from Continuing Operations, Per Diluted Share Net loss per share from continuing operations - diluted Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Net loss per share from discontinued operations - basic Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share Net loss per share from discontinued operations - diluted Earnings Per Share, Basic Net loss per share - Basic (In dollar per share) Earnings Per Share, Diluted Net loss per share - Diluted (In dollar per share) Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted-average number of shares used in computing net loss per share: Weighted Average Number of Shares Outstanding, Basic Basic (In shares) Weighted-average common shares outstanding - Basic Weighted Average Number of Shares Outstanding, Diluted Diluted (In shares) Weighted-average common shares outstanding - Diluted Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive loss: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive loss: OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized loss on available-for-sale securities, net of tax Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss Condensed Consolidated Statements of Stockholders' Equity (Deficit) Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-In Capital AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss Retained Earnings [Member] Accumulated Deficit Sale of Stock [Axis] Sale of Stock [Domain] Represents information pertaining to public offering. Public Offering Public offering Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance of common stock upon exercise of stock options (in shares) Stock Issued During Period, Value, Restricted Stock Award, Gross Issuance of common stock upon vesting of RSUs Stock Issued During Period, Shares, Restricted Stock Award, Gross Issuance of common stock upon vesting of RSUs (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock, net of issuance costs Common stock Stock Issued During Period, Shares, New Issues Issuance of common stock, net of issuance costs (in shares) Number of common stock shares sold during the period Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Taxes paid related to net share settlement of RSUs Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Taxes paid related to net share settlement of RSUs (in shares) APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Other Comprehensive Income (Loss), Net of Tax Other comprehensive loss, net of tax Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense Gain (Loss) on Sale of Interest in Projects Loss on Sale Transactions, net (Note 6) The change in fair value of derivatives. Change In Fair Value Of Derivatives Change in fair value of derivatives Other Operating Activities, Cash Flow Statement Other non-cash adjustments, net Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Receivables Trade receivables, net Increase (Decrease) in Inventories Inventory Increase in inventory Increase (Decrease) in Prepaid Expense Prepaid manufacturing Increase (Decrease) in Prepaid Expense and Other Assets Other prepaid, current and non-current assets Increase (Decrease) in Accounts Payable, Trade Accounts payable Increase decrease in accrued rebates, fees and reserve. Increase Decrease In Accrued Rebates Fees And Reserve Accrued rebates, fees and reserves Increase (Decrease) in Other Operating Assets and Liabilities, Net TSA related operating assets and liabilities, net TSA related operating assets and liabilities Increase decrease in accrued compensation. Increase Decrease In Accrued Compensation Accrued compensation Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued and other current and non-current liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities Payments to Acquire Marketable Securities Purchases of investments in marketable securities Proceeds from Sale and Maturity of Marketable Securities Proceeds from maturities of investments in marketable securities Payments for (Proceeds from) Productive Assets Cash paid related to the Sale Transactions (Note 6) The cash outflow associated with milestone based license fee payment. Payments For Milestone Based License Fee Milestone payment to Junshi Biosciences Payments for (Proceeds from) Other Investing Activities Other investing activities, net Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities Proceeds from Issuance of Common Stock Proceeds from issuance of common stock under Public Offering, net of issuance costs Net proceeds Proceeds from Issuance of Private Placement Proceeds from issuance of common stock under Private Placement, net of issuance costs Payment, Tax Withholding, Share-Based Payment Arrangement Taxes paid related to net share settlement Repayments of Convertible Debt Redemption of 2026 Convertible Notes, including transaction costs Cash paid to repurchase debt Proceeds from (Payments for) Other Financing Activities Other financing activities, net Net Cash Provided by (Used in) Financing Activities Net cash provided by (used in) financing activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Organization and Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Organization and Summary of Significant Accounting Policies Revenue Revenue from Contract with Customer [Text Block] Revenue Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Inventory and Prepaid Manufacturing Inventory Disclosure [Text Block] Inventory and Prepaid Manufacturing Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Balance Sheet Components Discontinued Operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Discontinued Operations Collaboration and license agreements. Collaborations and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Collaborations and Other Arrangements Financial Liabilities Debt Disclosure [Text Block] Financial Liabilities Commitments and Contingencies. Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Stockholders' Equity (Deficit) Disclosure containing information regarding Stockholders' Deficit. Stockholders Deficit Stockholders' Equity (Deficit) Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Earnings Per Share [Text Block] Net Loss Per Share Consolidation, Policy [Policy Text Block] Basis of Consolidation and Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Segment reporting and revenue by geographic region. Segment Reporting And Revenue By Geographic Region Policy [Text Block] Segment Reporting and Geographic Disclosures Revenue [Policy Text Block] Royalty Revenue New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Disaggregation of Revenue [Table Text Block] Schedule of Net product revenue in United States, and Company's net revenue Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedule of Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues Schedule of product sales discounts and allowances. Schedule Of Product Sales Discounts And Allowances Table [Text Block] Schedule of Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Financial Assets and Liabilities Measured on a Recurring Basis Cash, Cash Equivalents and Investments [Table Text Block] Schedule of Cash and cash equivalents, marketable securities and restricted cash Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of Goodwill and Intangible Assets, Net Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Liabilities Other Noncurrent Liabilities [Table Text Block] Schedule of Other Liabilities, Non-current Disposal Groups, Including Discontinued Operations [Table Text Block] Schedule of reconciliation of discontinued operations, net revenue from discontinued operations, derecognized assets and balance sheet classifications Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Table] Debt Instrument [Axis] Debt Instrument, Name [Domain] Represents information pertains to Revenue Purchase and sale agreement. Revenue Purchase and Sale Agreement Revenue Purchase and Sale Agreement Represents the information pertaining to 1.5% Convertible Senior Subordinated Notes due 2026. 1.5% Convertible Senior Subordinated Notes due 2026 2026 Convertible Notes Debt Instrument [Line Items] Financial Liabilities Net Loss Per Share Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Schedule of Company's Debt Obligations Tabular disclosure of royalty participation liability. Schedule Of Royalty Participation Liability [Table Text Block] Schedule of royalty participation liability Interest Income and Interest Expense Disclosure [Table Text Block] Schedule of Components of Interest Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of Stock-Based Compensation Expense Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Computation of Basic and Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net Loss Per Share Number of Operating Segments Number of operating segments Number of Reportable Segments Number of reportable segments Disaggregation of Revenue [Table] Product and Service [Axis] Product and Service [Domain] Product [Member] Total net product revenue Represents toripalimab. Toripalimab LOQTORZI Product and Service, Other [Member] Other revenue Disaggregation of Revenue [Line Items] Revenue Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Revenue Benchmark [Member] Net Product Revenue Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer Concentration Risk [Member] Customer Concentration Risk Customer [Axis] Customer [Domain] McKesson. McKesson Cencora inc. (previously known as AmeriSource-Bergen Corporation) Cencora, Inc. [Member] Cencora, Inc. Cardinal. Cardinal Cardinal Health, Inc. Concentration Risk [Line Items] Concentration Risk Concentration Risk, Percentage Percentage of total gross revenue Accounts and Financing Receivables [Table] Schedule Of Accounts Notes Loans And Financing Receivable [Table] Receivable Type [Axis] Receivable [Domain] Charge backs and discounts for prompt payment. Chargebacks and Discounts for Prompt Payment Rebates. Rebates Other fees, co-pay assistance and returns. Other Fees, Co-pay Assistance and Returns Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts Notes And Loans Receivable Reserve for discounts and allowances constitute variable consideration. Reserve For Discounts And Allowances Constitute Variable Consideration Activities and reserve balance, ending balance Activities and reserve balance, beginning balance n/a Provision related to sales made in: Reserve for sales discounts and allowances constitute variable consideration. Reserve For Sales Discounts And Allowances Constitute Variable Consideration Current year Represents provision related to sales made in prior period. Provision Related to Sales Made in Prior Period Prior years - increase (decrease) Payments and customer credits issued from reserve in discounts and allowances constitute variable consideration. Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration Payments and customer credits issued Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Disposal Group Name [Axis] Disposal Group Name [Domain] Represents the information pertaining to UDENYCA, a biosimilar to Neulasta (a long-acting G-CSF), and LOQTORZI, a next-generation PD-1 inhibitor. UDENYCA business [Member] UDENYCA Operating Activities [Axis] Operating Activities [Domain] Discontinued Operations [Member] Discontinued Operations Represents LOQTORZI. LOQTORZI LOQTORZI Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Financial assets measured at fair value on a recurring basis Cost, Unrealized Gains or Losses, and Fair Value by Investment Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Charge recorded Maximum remaining period until maturity of the investment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Contractual Maturities of Available-for-sale Debt Securities, Remaining Maturity Remaining contractual maturities of available-for-sale securities Average remaining period until maturity of the acquired debt security contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Remaining Contractual Maturities of Available-for-sale Debt Securities, Acquisition Average maturity of investments upon acquisition Debt Securities, Available-for-Sale, Allowance for Credit Loss Expected credit losses Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Fair Value Measurements Recurring Basis Asset Class [Axis] Asset Class [Domain] Cash and Cash Equivalents [Member] Cash equivalents Financial Instrument [Axis] Financial Instruments [Domain] US Government Agencies Debt Securities [Member] U.S. government agency securities US Treasury Securities [Member] U.S. treasury securities Corporate Note Securities [Member] Commercial paper and corporate notes Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Inputs, Level 2 [Member] Level 2 Fair Value, Inputs, Level 3 [Member] Level 3 Liability Class [Axis] Fair Value by Liability Class [Domain] Derivative Financial Instruments, Liabilities [Member] Royalty Fee Derivative Liability Assets, Fair Value Disclosure Total financial assets Financial Liabilities Fair Value Disclosure Total financial liabilities Money Market Funds [Member] Money market funds Debt Securities, Available-for-Sale, Amortized Cost Cost Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Unrealized Gain Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Unrealized (Loss) Debt Securities, Available-for-Sale Fair Value Inventory, Current [Table] Inventory Current [Table] Inventory [Line Items] Inventory Amount of inventory including current and noncurrent. Inventory Current And Noncurrent Inventory current and noncurrent Amount of inventory finished goods including current and noncurrent. Inventory, Finished Goods, Current And Noncurrent Inventory finished goods current and noncurrent Amount of inventory work in progress including current and noncurrent. Inventory, Work in Process, Current And Noncurrent Inventory work in progress current and noncurrent Inventory, Finished Goods, Gross Finished goods Represents prepayments made to a CMO for other research and development program. Prepayments made to a CMO For Other Research And Development Pipeline Program Prepayments made to a CMO For Other Research And Development Pipeline Program Represents prepayments made to a CMO for manufacturing services. Prepayments Made to CMO For Manufacturing Services Prepayments made to a CMO for manufacturing services Collaborative Arrangement and Arrangement Other than Collaborative [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions Finite-Lived Intangible Assets, Net Finite-lived assets, net Finite-Lived Intangible Assets, Accumulated Amortization Accumulated amortization Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite-lived assets - in-process research and development Amortization of Intangible Assets Amortization expense, Finite-lived intangible assets Accrued commercial and research and development manufacturing liabilities current. Accrued Commercial and Research and Development Manufacturing Liabilities Current Accrued commercial and research and development manufacturing Represents lease liabilities for both operating and financing leases. Lease Liabilities, Operating and Financing Lease liabilities, current Other Accrued Liabilities, Current Accrued other Deferred Income Tax Liabilities, Net Deferred tax liability Amount of obligations related to royalty participation, classified as noncurrent. Royalty Participation Liability, Noncurrent Revenue participation liability, non-current Derivative Liability, Noncurrent Royalty fee derivative liability, non-current Other Sundry Liabilities, Noncurrent Other Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Discontinued Operations, Disposed of by Sale [Member] Discontinued Operations Disposed of by Sale Scenario [Axis] Scenario [Domain] Represents the information pertaining to minimum net sales of discontinued operation for four consecutive fiscal quarters from the start of the quarter ending September 30, 2025 until the end of the quarter ending September 30, 2026, that would trigger payment of contingent asset receivable. Scenario, Net Sales Exceeding 300 million, Quarters Ending September 30, 2026 [Member] Scenario, net sales exceeding 300 million, quarters ending september 30, 2026 Represents the information pertaining to minimum net sales of discontinued operation for four consecutive fiscal quarters from the start of the quarter ending September 30, 2025 until the end of the quarter ending March 31, 2027, which would trigger payment of contingent asset receivable. Scenario, Net Sales Exceeding 350 million, Quarters Ending March 31, 2027 [Member] Scenario, net sales exceeding 350 million, quarters ending march 31, 2027 Represents term loans. 2027 Term Loans Business Acquisition [Line Items] Discontinued Operations Disposal Group, Including Discontinued Operation, Consideration Cash consideration Disposal Group, Including Discontinued Operation, Inventory Product Inventory Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Net gain Amount of transaction expense attributable to disposal group, including, but not limited to, discontinued operation. Disposal Group, Including Discontinued Operation, Transaction Expense Transaction expenses Amount represents the receivable for earnout payments that are contingent upon satisfaction of minimum net sales threshold. Discontinued Operation, Amounts of Material Contingent Assets Receivable Amount of each earnout payments The minimum required net sales of the discontinued operation during the specified period, which would trigger earnout payment. Threshold Net Sales, Payment Trigger Threshold net sales, payment trigger Debt Instrument, Face Amount Principal Amount Principal amount Disposal Groups, Including Discontinued Operations [Table] Discontinued Operations, Held-for-Sale [Member] Assets Held For Sale Represents the information pertaining to YUSIMRY immunology franchise. YUSIMRY Immunology Franchise [Member] YUSIMRY Sale YUSIMRY immunology franchise Represents the information pertaining to CIMERLI ophthalmology franchise. CIMERLI Ophthalmology Franchise [Member] CIMERLI ophthalmology franchise CIMERLI Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Discontinued Operations Disposal Group, Including Discontinued Operation, Revenue Net revenue Total net revenue from discontinued operations No definition available. Disposal Group, Including Discontinued Operation, Costs and Expenses [Abstract] Costs and expenses: Disposal Group, Including Discontinued Operation, Costs of Goods Sold Cost of goods sold Amount of selling, general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation. Disposal Group, Including Discontinued Operation, Selling, General and Administrative Expense Selling, general and administrative Amount of total costs and expenses attributable to disposal group, including, but not limited to, discontinued operation. Disposal Group, Including Discontinued Operation, Total Costs and Expenses Total costs and expenses Disposal Group, Including Discontinued Operation, Operating Income (Loss) Income from operations Disposal Group, Including Discontinued Operation, Interest Expense Interest expense Interest expense, discontinued operation Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Loss on Sale Transactions, net Amount of other income (expense), net, attributable to disposal group, including, but not limited to, discontinued operation. Disposal Group, Including Discontinued Operation, Other Income (expense), Net Other income (expense), net Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Net income from discontinued operations before income taxes Amount of accounts receivables net of charge off. Accounts receivables net of charge off Trade receivables, net Liabilities [Abstract] Liabilities Amount of increase (decrease) in the fair value of royalty fee derivative liability attributable to disposal group, including, but not limited to, discontinued operation. Net gain Change in fair value Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Represents information pertaining to Junshi Biosciences. Junshi Biosciences Junshi Biosciences Represents information pertaining to Canada License Agreement. Canada License Agreement [Member] Canada license agreement with Apotex Represents the Vaccinex License Agreement. Vaccinex License Agreement [Member] Vaccinex License Agreement Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Domain] Represents intangible assets, net and accrued and other current liabilities. Intangible Assets, Net And Accrued And Other Current Liabilities [Member] Intangible assets, net and accrued and other current liabilities Accrued Royalties Royalties due Carrying value as of the balance sheet date of obligations incurred through that date and payable for milestone payments. Accrued Milestone Payment Accrued milestone payment Amount per each installment of milestone payments under collaborative arrangements. Milestone Payments, Amount Per Each Installment Milestone payments, amount The upfront payment received by the company under the collaborative arrangement. Collaborative Arrangement Upfront Payment Received Company an upfront payment received Amount of regulatory and sales milestones eligible to receive under the collaborative arrangement. Collaborative Arrangement, Regulatory And Sales Milestones Eligible To Receive Regulatory and sales milestones eligible to receive Represents the percentage of royalty on net sales under the collaboration agreement. Collaboration Agreement, Percentage Of Royalty On Net Sales Collaboration agreement, royalty on net sales, percentage Renewal term of agreement. Collaboration Agreement, Renewal Term Renewal term Maximum aggregate milestone payments to be made Collaboration Agreement, Maximum Aggregate Milestone Payments to be Made Maximum aggregate milestone payments to be made Amount of regulatory milestones eligible to pay. Regulatory Milestones Eligible to Pay Maximum aggregate amount payable for achievement of certain clinical milestones low single digit royalties on global net sales of any approved licensed products Clinical payment associated with milestone based license fee payment. Milestone Payments Paid For License Fee Clinical milestone payments Represents 2029 term loans. Two Thousand Twenty Nine Term Loans [Member] 2029 Term Loans Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Less unamortized debt discount and issuance costs Long-Term Debt Net carrying amount Debt Instrument, Fair Value Disclosure Estimated Fair Value Counterparty Name [Axis] Counterparty Name [Domain] Represents information pertaining to Ankura Trust Company LLC. Ankura Trust Company LLC [Member] Ankura Trust Company, LLC Proceeds from Debt, Net of Issuance Costs Net proceeds, net of original issuance discount Debt Instrument, Interest Rate, Stated Percentage Stated interest rate Number of events in default. Number Of Events in Default Number of events in default Interest Expense, Debt Interest expense Total Interest expense Embedded Derivative [Table] Represents information relating to the product UDENYCA. Udenyca [Member] UDENYCA Represents Udenyca and Loqtorzi. Udenyca and Loqtorzi [Member] UDENYCA and LOQTORZI Embedded Derivative [Line Items] Revenue Purchase and Sale Agreement purchase price. Revenue Purchase and Sale Agreement, Purchase Price Revenue Purchase and Sale Agreement, Purchase price The percent to be received pertaining to the sales of the companies products and services. Revenue Purchase and Sale Agreement, Right to Receive, Percent Revenue payment, Percentage of U.S. net sales Revenue Purchase and Sale Agreement purchase price. Revenue Purchase and Sale Agreement, Certain Conditions, Purchase Price, Multiplier Purchase price multiplier The cash outflow to buy out the right to receive future payments in accordance with agreement entered into by the company. Payments to Buy Out Right to Receive Future Payments Payments to buy out right to receive future payments Discount on the revenue participation liability, resulting from a derivative instrument. Discount On Revenue Participation Liability From Derivative Instrument Discount on revenue participation liability from allocation of purchase price to the embedded derivative Issuance costs on the revenue participation liability. Issuance Costs On Revenue Participation Liability Issuance costs on revenue participation liability Debt Instrument, Interest Rate, Effective Percentage Effective interest rate Amount of revenue participation liability. Revenue Participation Liability Revenue participation liability Amount of Obligations related to royalty participation. Royalty Participation Liability Balance at March 31 Balance at January 1 Net carrying value Amount of cash outflow for royalty payments under revenue participation liability. Revenue Participation Liability, Royalty Revenue Payment Royalty payments Interest expense, inclusive of the amortization of discount and issuance costs. Interest Expense, Inclusive Of Amortization Of Discount And Issuance Costs On Revenue Participation Liability Interest expense recognized Amount of interest expense attributable to continuing operation. Interest Expense, Continuing Operation Interest expense, continuing operation Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] Convertible Debt [Member] Debt Instrument, Interest Rate Terms Interest rate description Debt Instrument, Maturity Date Debt instrument maturity date Extinguishment of Debt, Amount Aggregate principal amount Debt Instrument, Redemption Price, Percentage Percentage of redemption price Debt Instrument, Repurchase Amount Repurchase Amount Interest Expense, Debt, Excluding Amortization Stated coupon interest Amortization of Debt Discount (Premium) Amortization of debt discount and debt issuance costs Contractual Obligation Fiscal Year Maturity [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Other Commitments [Axis] Other Commitments [Domain] Represents the information pertaining to inventory replacement commitment under Legacy customer agreement. Legacy Customer Agreement, Inventory Replacement Commitment [Member] Legacy customer agreement Loss Contingencies [Line Items] Commitments and Contingencies Purchase Obligation, to be Paid, Year One Purchase obligation Maximum amount of potential commitment exposure. Maximum Potential Commitment Exposure Maximum potential commitment exposure At the market offering. Stockholders' Deficit [Table] Represents information relating to a sales agreement. Sales Agreement [Member] Sales agreement Private Placement [Member] Private placement Over-Allotment Option [Member] Underwriters' Option to Purchase Additional Shares Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum [Member] Maximum Line items represent at the market offering. At The Market Offering [Line Items] Stockholders' Deficit Represents the common stock remaining available for sale under the atm offering. Common Stock Remaining Available For Sale Under The ATM Offering Common stock remaining available for sales under the ATM Offering Class of Warrant or Right, Date from which Warrants or Rights Exercisable Class of Warrant or Right, Number of Securities Called by Warrants or Rights Class of Warrant or Right, Exercise Price of Warrants or Rights Sale of Stock, Consideration Received on Transaction Common stock, net proceeds Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date Number of warrants exercise during the period. Warrants Exercises During Period Exercise shares Sale of Stock, Number of Shares Issued in Transaction Aggregate shares The period for exercise of option to purchase additional shares by underwriters. Shares Offering, Underwriters Option, Term Term of share offering Shares Issued, Price Per Share Share price Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Cost of Sales [Member] Cost of goods sold Research and Development Expense [Member] Research and development Selling, General and Administrative Expenses [Member] Selling, general and administrative Continuing Operations [Member] Continuing Operations Share-Based Payment Arrangement, Expense Stock-based compensation expense Share-Based Payment Arrangement, Amount Capitalized Total stock-based compensation expense capitalized into inventory Income (Loss) from Continuing Operations Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period, attributable to continuing operations. Weighted Average Number of Shares Outstanding, Basic, Continuing Operations Weighted-average common shares outstanding from continuing operations, basic The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period, attributable to continuing operations. Weighted Average Number of Shares Outstanding, Diluted, Continuing Operations Weighted-average common shares outstanding from continuing operations, diluted Income from Discontinued Operations Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period, attributable to discontinued operations. Weighted Average Number of Shares Outstanding, Basic, Discontinued Operations Weighted-average common shares outstanding from discontinued operations, basic The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period, attributable to discontinued operations. Weighted Average Number of Shares Outstanding, Diluted, Discontinued Operations Weighted-average common shares outstanding from discontinued operations, diluted Antidilutive Security, Excluded EPS Calculation [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Employees and non-employees stock option. Stock options, including shares subject to ESPP Stock options, PSOs, including shares subject to ESPP Restricted Stock Units (RSUs) [Member] Restricted stock units Convertible notes. Shares issuable upon conversion of convertible notes Shares Issuable Upon Conversion of Convertible Notes Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of EPS Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from the calculation of diluted net loss per share Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures, including those attributable to disposal group held for sale or disposed of. Property, Plant and Equipment, Including Discontinued Operations, Net